Innovative Therapeutics in Oncology and Neuroscience
Efgartigimod (SC)
Opportunity to Transform CIDP Patient Experience (ADHERE Study)
ESTABLISHED CIDP
AS IgG MEDIATED
Stage A
67%
Stage B
Response rate demonstrates
IgG autoantibodies
play significant role in
underlying CIDP biology
SET NEW
STANDARD FOR
61%
HOW CIDP
TRIALS ARE RUN
Reduced risk
of relapse
Probability (%) of no relapse (alNCAT)
100-
HR: 0.39
P = 0.000039
75
50
25
0.
0 4
8
12 16
20 24 28 32 36 40
Time (Weeks)
44 48
# patients at risk
Placebo.
Vyvgart Hytrulo 111 107 93
110 94
80 68
67 55 51 47 38 31
56 55
48
42
40 36 36 28
28 26 24 21
16
+
SIGNIFICANT IMPACT
ON CIDP PATIENTS
99%
Study Compliance
99%
Rollover of eligible patients
to open-label extension
Favorable safety and tolerability profile
consistent with previous clinical trials
Late-stage
U.S. SBLA accepted with PDUFA goal date of Jun 21, 2024; Potential China sBLA submission in 1H'24
Clinical Data
Autoimmune
40
Source: argenx corporate presentations, January 2024.View entire presentation